11.12.2012
- Denmark's Novo Nordisk is sizing up a high-price niche market for its drug liraglutide as a weight-loss treatment, with the United States the prime opportunity. The premium-price...
20.04.2012
- Watchdog group Public Citizen urged U.S. regulators to withdraw approval of Novo Nordisk's diabetes drug Victoza, saying it increases the risk of serious health problems like...
